Over a quarter ago |
Hot Stocks
|
COMPASS Pathway is… COMPASS Pathway is establishing its first Centre of Excellence in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland, United States. The company said, "The Centre of Excellence will model the "clinic of the future", showcasing the best thinking in science, therapy, technology, and design. Working as a research facility and innovation lab, it will generate evidence to shape therapy models in mental health care, train and certify therapists, conduct clinical trials including proof-of-concept studies, and prototype digital solutions to improve patient experience. The first wave of research will focus on COMPASS's investigational COMP360 psilocybin therapy, which comprises administration of COMP360 psilocybin with psychological support from specially trained therapists...The Centre of Excellence will be led by Scott Aaronson MD, Director of Clinical Research at Sheppard Pratt, a distinguished fellow of the American Psychiatric Association and a fellow of the American College of Psychiatrists. The Centre of Excellence will be built on the Sheppard Pratt Towson campus and will include at least four state-of-the-art psychedelic therapy rooms, as well as facilities for research and training. In addition to a capital investment to support the design and building work, COMPASS will fund research studies into psilocybin therapy and other therapies, led by Dr Aaronson. " ShowHide Related Items >><< - 11/12/20
- Compass Pathways expects cash, cash equivalents to fund operations into 2023
- 11/09/20
- Compass Pathways joins the Psychiatry Consortium
- 10/23/20
- Compass Pathways CEO says 'focus is on transforming mental healthcare'
- 10/05/20
- Citron touts mental health company Compass Pathways, sets $100 target on shares
- 10/14/20 H.C. Wainwright
- Compass Pathways initiated with a Buy at H.C. Wainwright
- 10/13/20 Evercore ISI
- Compass Pathways initiated with an Outperform at Evercore ISI
- 10/13/20 Canaccord
- Compass Pathways initiated with a Buy at Canaccord
- 10/13/20 Berenberg
- Compass Pathways initiated with a Buy at Berenberg
- 11/12/20
- Compass Pathways reports Q3 EPS ($1.30), consensus (56c)
|
Conference/Events
|
3rd Annual HealthCONx… 3rd Annual HealthCONx Virtual Conference will be held on December 1-3. ShowHide Related Items >><< - 08/04/20
- Zimmer Biomet saw incremental improvement in May, June
- 10/15/20
- Sanofi, Translate Bio: COVID-19 vaccine candidate induced high antibody levels
- 10/07/20
- Translate Bio announces upcoming presentations at NACFC
- 09/08/20
- Translate Bio resumes enrollment, dosing in Phase 1/2 trial of MRT5005
- 06/23/20
- Sanofi Pasteur, Translate Bio expand collaboration to develop mRNA vaccines
- 09/09/20
- Sutro Biopharma reports Phase 1 data of STRO-002 in ovarian cancer
- 09/02/20
- Sutro Biopharma reports 'promising' interim Phase 1 clinical data from STRO-002
- 08/25/20
- Sutro Biopharma achieves clinical supply milestone with Merck
- 06/22/20
- Sutro Biopharma presents new data on STRO-002
PRAX Praxis Precision Medicines - 12/01/20
- Praxis CFO Stuart Chaffee transitions to part-time role as strategic advisor
- 11/17/20
- Praxis Precision expects to initiate Phase 2/3 trial for PRAX-114 in 1H21
- 11/09/20
- FDA places Praxis Precision Medicines' PRAX-114 IND on full clinical hold
- 10/30/20
- Envista rises 10.7%
- 08/04/20
- Dentsply Sirona, Patterson higher as Henry Schein discusses July trends on call
- 11/12/20
- Nkarta announces first patient treated in NKX101 trial
- 11/09/20
- Nkarta announces preclinical update on NKX019
- 10/05/20
- Nkarta CFO Matthew Plunkett steps down, Nadir Mahmood succeeds
- 07/24/20
- Ra Capital reports 17.2% stake in Nkarta
- 06/22/20
- Molecular Templates provides update on Phase 1 study of MT-5111
- 06/22/20
- Molecular Templates highlights ETB platform at AACR Annual Meeting
- 11/06/20
- Seres Therapeutics doses first patient in SER-301 trial
- 10/22/20
- Seres Therapeutics appoints David Ege as CTO, Jayne Gansler as CPO
- 09/11/20
- Seres Therapeutics announces FDA correspondence regarding SER-109 BLA
- 08/10/20
- Seres Therapeutics soars 170% after 'positive' results from Phase 3 ECOSPOR III
- 11/16/20
- Kodiak Sciences completes enrollment of DAZZLE study of KSI-301
- 10/05/20
- Kodiak Sciences: First patients treated in Phase 3 Studies of KSI-301
- 07/10/20
- Kodiak Sciences reports 'promising' safety data from KSI-301 Phase 1b study
- 12/02/20
- Insmed initiates Phase 3 study of Brensocatib in patients with bronchiectasis
- 11/13/20
- Insmed's Brensocatib receives EMA priority medicines designation for NCFBE
- 10/28/20
- Insmed: EC grants marketing authorization for ARIKAYCE
- 09/07/20
- Results from Insmed's Phase 2 WILLOW study of brensocatib published in NEJM
- 11/30/20
- MacroGenics achieves $25M in milestones related to retifanlimab collaboration
- 11/19/20
- Eli Lilly, Incyte: FDA issues EUA for baricitinib/remdesivir combination
- 11/11/20
- Incyte, Xencor, MorphoSys to collaborate over tafasitamab-plamotamab combo
- 11/11/20
- Xoma earns $1M milestone payment from 2018 royalty purchase agreement
- 10/21/20
- Icon says COVID-19 impact reduced in recent months
- 07/22/20
- Icon shareholders vote in favor of all resolutions at annual meeting
- 07/28/20
- Hill-Rom announces commercial partnership with Aiva for hands-free communication
- 12/01/20
- Amicus initiates rolling BLA for AT-GAA in late-onset Pompe disease
- 11/05/20
- Amicus plans to initiate rolling BLA for AT-GAA in 2020
- 11/05/20
- Amicus sees FY20 Galafold revenue of $250M-$260M
- 10/12/20
- Amicus announces additional interim clinical data for AT-GTX-501
- 11/16/20
- Fate Therapeutics director sells 25K shares of common stock
- 08/19/20
- Fate Therapeutics appoints Edward Dulac as CFO
- 08/12/20
- Fate Therapeutics' FT516 receives support from CIRM Late Stage Preclinical grant
- 07/14/20
- Fate Therapeutics announces license agreement with Baylor College of Medicine
- 12/02/20
- Exelixis exercises option for Iconic's ADC, to develop under May 2019 pact
- 11/27/20
- Exelixis says Takeda receives approval for CABOMETYX in Japan
- 10/27/20
- Exelixis announces Takeda, Ono submit application for Cabometyx in Japan
- 10/26/20
- Exelixis announces 1st patient enrolled trial cohort evaluating XL092 in combo
- 09/14/20
- Enanta initiates Phase 1 clinical study of EDP-297
- 08/28/20
- Enanta to present data from hepatitis B virus, NASH programs at EASL
- 07/09/20
- Enanta announces clinical trial progress for ED-514
- 11/16/20
- Dicerna gets $10M milestone from Lilly pact, Lilly initiates LY3561774 trial
- 11/16/20
- Dicerna presents data from phase1 trial of RG6346 for hep B at AASLD
- 10/22/20
- Dicerna reports 'positive' new interim data from PHYOX3 trial
- 09/16/20
- Dicerna appoints Ling Zeng as chief legal officer
- 11/30/20
- Cogent Biosciences appoints Brad Barnett as Chief Technology Officer
- 11/18/20
- Cogent Biosciences reports final Phase 2 results from PLX9486 in GIST
- 10/26/20
- Cogent Biosciences names Andrew Robbins as CEO, succeeding Chuck Wilson
- 11/12/20
- Compass Pathways expects cash, cash equivalents to fund operations into 2023
- 11/09/20
- Compass Pathways joins the Psychiatry Consortium
- 10/23/20
- Compass Pathways CEO says 'focus is on transforming mental healthcare'
- 10/05/20
- Citron touts mental health company Compass Pathways, sets $100 target on shares
- 11/24/20
- Bausch Health begins second of Phase 3 studies of NOV03
- 11/16/20
- Paulson & Co. buys Lear, cuts Tiffany in Q3
- 11/16/20
- Bausch Health reports in vitro data on Lumify, Besivance in SARS-CoV-2
- 10/29/20
- Bausch Health's rifaximin Receives FDA Orphan Designation
- 11/25/20
- Alexion granted orphan status for hematopoietic stem cell treatment
- 11/20/20
- Alexion receives marketing authorization from EC for Ultomiris 100mg
- 10/12/20
- Alexion gets FDA Aaproval for Ultomoris
- 10/06/20
- Alexion expects to raise FY20 revenue guidance by more than $200M
- 10/14/20 H.C. Wainwright
- Compass Pathways initiated with a Buy at H.C. Wainwright
- 10/13/20 Evercore ISI
- Compass Pathways initiated with an Outperform at Evercore ISI
- 10/13/20 Canaccord
- Compass Pathways initiated with a Buy at Canaccord
- 10/13/20 Berenberg
- Compass Pathways initiated with a Buy at Berenberg
- 11/23/20 Evercore ISI
- Insmed resumed with an Outperform at Evercore ISI
- 11/23/20 Evercore ISI
- Insmed resumed with an Outperform at Evercore ISI
- 10/12/20 Stifel
- Insmed resumed with a Buy at Stifel
- 04/23/20 JMP Securities
- JMP reiterates $50 target on Insmed on planned COVID-19 trial
- 11/20/20
- Fly Intel: Top five analyst initiations
- 11/20/20 Bernstein
- Alexion initiated with a Market Perform at Bernstein
- 11/19/20 Bernstein
- Alexion initiated with a Market Perform at Bernstein
- 11/05/20 Citi
- Alexion price target raised to $157 from $145 at Citi
- 11/24/20 RBC Capital
- Enanta price target lowered to $45 from $52 at RBC Capital
- 11/24/20 Evercore ISI
- Evercore cautious on Enanta into 2021, starts with Underperform
- 11/23/20 Evercore ISI
- Enanta initiated with an Underperform at Evercore ISI
- 10/26/20 Roth Capital
- Enanta price target raised to $107 from $104 at Roth Capital
- 10/06/20 Mizuho
- Nkarta CFO departure should not impact shares, says Mizuho
- 08/04/20 Mizuho
- Mizuho starts Nkarta with Buy rating, $34 price target
- 08/04/20 Evercore ISI
- Nkarta initiated with an Outperform at Evercore ISI
- 08/04/20 Stifel
- Nkarta initiated with a Buy at Stifel
- 11/04/20
- Fly Intel: Top five analyst downgrades
- 11/04/20
- Hill-Rom cut to Hold at Needham, expecting 'lost year' in FY21
- 11/04/20 Needham
- Hill-Rom downgraded to Hold from Buy at Needham
- 10/01/20 KeyBanc
- Hill-Rom price target lowered to $115 from $138 at KeyBanc
- 08/07/20 H.C. Wainwright
- Dicerna price target raised to $35 from $32 at H.C. Wainwright
- 07/01/20 Baird
- Dicerna elevated to Fresh Pick at Baird
- 05/12/20 RBC Capital
- Dicerna initiated with an Outperform at RBC Capital
- 05/11/20 Truist
- Dicerna price target raised to $33 from $28 at SunTrust
- 11/09/20 SVB Leerink
- Zimmer Biomet price target raised to $167 from $160 at SVB Leerink
- 11/09/20 Credit Suisse
- Zimmer Biomet price target raised to $106 from $99 at Credit Suisse
- 11/09/20 Baird
- Zimmer Biomet valuation discount to peers hard to justify, says at Baird
- 11/09/20 Oppenheimer
- Zimmer Biomet price target raised to $155 from $150 at Oppenheimer
- 11/06/20 RBC Capital
- Incyte price target lowered to $86 from $96 at RBC Capital
- 09/18/20 Piper Sandler
- Piper Sandler lays out next potential takeover targets in oncology
- 09/14/20 Mizuho
- Oncology 'fertile ground for M&A activity,' says Mizuho
- 08/05/20 Mizuho
- Incyte price target raised to $95 from $79 at Mizuho
- 09/08/20 Jefferies
- Molecular Templates initiated with a Buy at Jefferies
- 08/07/20
- Molecular Templates files $300M mixed securities shelf
- 05/12/20 Oppenheimer
- Molecular Templates price target raised to $22 from $16 at Oppenheimer
- 03/25/20
- Fly Intel: Top five analyst initiations
- 11/30/20
- Fly Intel: Top five analyst downgrades
- 11/30/20 JPMorgan
- Kodiak Sciences downgraded to Neutral on valuation at JPMorgan
- 11/30/20 JPMorgan
- Kodiak Sciences downgraded to Neutral from Overweight at JPMorgan
- 11/16/20 Morgan Stanley
- Morgan Stanley downgrades Kodiak to Equal Weight on lack of near-term catalysts
- 10/23/20 Deutsche Bank
- Icon price target raised to $179 from $170 at Deutsche Bank
- 10/23/20 Mizuho
- Icon price target raised to $217 from $195 at Mizuho
- 10/22/20 Credit Suisse
- Icon price target raised to $235 from $230 at Credit Suisse
- 07/27/20 Truist
- SunTrust raises price targets on select late-stage CROs
- 11/09/20 Oppenheimer
- Seres Therapeutics price target raised to $38 from $34 at Oppenheimer
- 11/09/20 Piper Sandler
- Seres Therapeutics price target raised to $49 from $40 at Piper Sandler
- 10/27/20 Oppenheimer
- Seres Therapeutics price target raised to $34 from $29 at Oppenheimer
- 10/26/20 Oppenheimer
- Seres Therapeutics price target raised to $34 from $29 at Oppenheimer
- 10/30/20 JPMorgan
- Envista price target raised to $30 from $28 at JPMorgan
- 10/30/20 Piper Sandler
- Envista price target raised to $28 from $22 at Piper Sandler
- 07/31/20 Piper Sandler
- Envista price target raised to $22 from $20 at Piper Sandler
- 06/16/20
- Fly Intel: Top five analyst initiations
- 10/26/20 Piper Sandler
- Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
- 09/22/20 Morgan Stanley
- Exelixis price target raised to $29 from $23 at Morgan Stanley
- 09/21/20 Piper Sandler
- Exelixis price target raised to $33 from $30 at Piper Sandler
- 06/30/20 Piper Sandler
- Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
- 12/02/20 Barclays
- Fate Therapeutics price target raised to $70 from $60 at Barclays
- 11/24/20 Truist
- Fate Therapeutics price target raised to $65 from $40 at Truist
- 11/09/20 Citi
- Fate Therapeutics price target raised to $63 from $40 at Citi
- 11/08/20 Oppenheimer
- Fate Therapeutics price target raised to $60 from $40 at Oppenheimer
- 11/11/20 Berenberg
- Biotechnology companies initiated at Berenberg
- 11/11/20 Berenberg
- Amicus initiated with a Hold at Berenberg
- 11/06/20 Baird
- Amicus price target raised to $25 from $20 at Baird
- 08/11/20 Citi
- Amicus price target raised to $20 from $15 at Citi
- 11/10/20 Wedbush
- Cogent Biosciences price target raised to $24 from $6 at Wedbush
- 10/14/20 Ladenburg
- Ladenburg starts Cogent Biosciences with Buy, $4 price target
- 10/14/20 Ladenburg
- Cogent Biosciences initiated with a Buy at Ladenburg
- 11/05/20 Piper Sandler
- Bausch Health price target lowered to $25 from $26 at Piper Sandler
- 10/26/20 Barclays
- Bausch Health price target raised to $29 from $28 at Barclays
- 09/17/20
- Fly Intel: Top five analyst upgrades
- 09/17/20 BofA
- Bausch Health upgraded to Neutral from Underperform at BofA
- 10/04/20 Goldman Sachs
- Translate Bio initiated with a Buy at Goldman Sachs
- 07/07/20 H.C. Wainwright
- Translate Bio price target raised to $32 from $18 at H.C. Wainwright
- 07/06/20
- Fly Intel: Top five analyst initiations
- 07/06/20 William Blair
- Translate Bio initiated with an Outperform at William Blair
- 12/02/20 Stifel
- Sutro Biopharma initiated with a Buy at Stifel
- 11/06/20 Piper Sandler
- Sutro Biopharma price target raised to $22 from $20 at Piper Sandler
- 09/02/20 Jefferies
- Sutro Biopharma initiated with a Buy at Jefferies
PRAX Praxis Precision Medicines - 11/17/20 Piper Sandler
- Praxis Precision clinical hold looks like 'formality,' says Piper Sandler
- 11/11/20
- Fly Intel: Top five analyst initiations
- 11/11/20 Wedbush
- Wedbush bullish on Praxis Precision Medicines, initiates with an Outperform
- 11/11/20 Wedbush
- Praxis Precision Medicines initiated with an Outperform at Wedbush
- 11/06/20
- Zimmer Biomet not providing Q4 guidance
- 11/06/20
- Zimmer Biomet reports Q3 adjusted EPS $1.81, consensus $1.07
- 08/04/20
- Zimmer Biomet not providing FY20 guidance due to COVID-19
- 08/04/20
- Zimmer Biomet reports Q2 adj. EPS 5c, consensus (73c)
- 11/05/20
- Sutro Biopharma reports Q3 EPS 45c, consensus (51c)
- 08/06/20
- Sutro Biopharma reports Q2 EPS (94c), consensus (64c)
- 10/29/20
- Envista reports Q3 adjusted EPS 48c, consensus 9c
- 07/30/20
- Envista reports Q2 adjusted EPS (10c), consensus (22c)
- 11/05/20
- Molecular Templates cash, equivalents expected to fund operations into 2H22
- 11/05/20
- Molecular Templates reports Q3 EPS (47c), consensus (55c)
- 08/06/20
- Molecular Templates reports Q2 EPS (68c), consensus (36c)
- 11/09/20
- Seres Therapeutics reports Q3 EPS ,(36c) consensus (25c)
- 07/28/20
- Seres Therapeutics reports Q2 EPS (28c), consensus (26c)
- 11/09/20
- Kodiak Sciences reports Q3 EPS (80c), consensus (67c)
- 08/10/20
- Kodiak Sciences reports Q2 EPS (58c), consensus (66c)
- 10/29/20
- Insmed reports Q3 GAAP EPS (63c), consensus (61c)
- 08/06/20
- Insmed reports Q2 EPS (64c), consensus (63c)
- 11/05/20
- Incyte reports Q3 EPS 23c, consensus 75c
- 08/04/20
- Incyte reports Q2 EPS $1.24, consensus 87c
- 08/03/20
- Notable companies reporting before tomorrow's open
- 10/21/20
- Icon raises FY20 revenue view to $6.35-$6.50 from $6.00-$6.50
- 10/21/20
- Icon reports Q3 EPS $1.72, consensus $1.53
- 07/22/20
- Icon sees FY20 EPS $6.00-$6.50, consensus $5.95
- 07/22/20
- Icon reports Q2 adjusted EPS $1.20, consensus $1.10
- 11/06/20
- Hill-Rom sees FY21 adj. EPS $5.35-$5.45, consensus $5.38
- 11/06/20
- Hill-Rom sees Q1 adj. EPS $1.05-$1.10, consensus 96c
- 11/06/20
- Hill-Rom reports Q4 adj. EPS $1.17, consensus $1.07
- 07/31/20
- Hill-Rom reports Q3 adj. EPS $1.95, consensus $1.46
- 11/05/20
- Amicus reports Q3 EPS (25c), consensus (22c)
- 08/10/20
- Amicus sees 2020 Galafold revenue $250M-$260M, consensus $254.82M
- 08/10/20
- Amicus reports Q2 EPS (20c), consensus (26c)
- 07/17/20
- Amicus reaffirms 2020 Galafold revenue view $250M-$260M
- 11/05/20
- Fate Therapeutics reports Q3 EPS (40c), consensus (36c)
- 08/05/20
- Fate Therapeutics reports Q2 EPS (35c), consensus (27c)
- 11/05/20
- Exelixis sees FY20 revenue $900M-$950M, consensus $922M
- 11/05/20
- Exelixis reports Q3 adjusted EPS 4c, consensus 1c
- 08/06/20
- Exelixis sees FY20 revenue $900M-$950M, consensus $908.9M
- 08/06/20
- Exelixis reports Q2 EPS 25c, consensus 12c
- 11/23/20
- Enanta reports Q4 EPS ($1.46), consensus (95c)
- 08/04/20
- Enanta reports Q3 EPS (71c), consensus (84c)
- 11/05/20
- Dicerna reports Q3 EPS (29c), consensus (20c)
- 08/06/20
- Dicerna reports Q2 EPS (43c), consensus 10c
- 11/09/20
- Cogent Biosciences reports Q3 EPS ($5.07), consensus (14c)
- 11/12/20
- Compass Pathways reports Q3 EPS ($1.30), consensus (56c)
- 11/03/20
- Bausch Health reports Q3 adjusted EBITDA $948M, consensus $844.9M
- 11/03/20
- Bausch Health backs FY20 revenue view $7.8B-$8B, consensus $7.89B
- 11/02/20
- Notable companies reporting before tomorrow's open
- 10/29/20
- Alexion raises 2020 non-GAAP EPS view to $11.70-$12.00 from $10.65-$10.95
- 10/29/20
- Alexion reports Q3 non-GAAP EPS $3.24, consensus $2.60
- 10/28/20
- Notable companies reporting before tomorrow's open
|
Conference/Events
|
3rd Annual HealthCONx… 3rd Annual HealthCONx Virtual Conference will be held on December 1-3. ShowHide Related Items >><< - $146.00 /
-3.175 (-2.13%) - 08/04/20
- Zimmer Biomet saw incremental improvement in May, June
- 10/15/20
- Sanofi, Translate Bio: COVID-19 vaccine candidate induced high antibody levels
- 10/07/20
- Translate Bio announces upcoming presentations at NACFC
- 09/08/20
- Translate Bio resumes enrollment, dosing in Phase 1/2 trial of MRT5005
- 06/23/20
- Sanofi Pasteur, Translate Bio expand collaboration to develop mRNA vaccines
- 09/09/20
- Sutro Biopharma reports Phase 1 data of STRO-002 in ovarian cancer
- 09/02/20
- Sutro Biopharma reports 'promising' interim Phase 1 clinical data from STRO-002
- 08/25/20
- Sutro Biopharma achieves clinical supply milestone with Merck
- 06/22/20
- Sutro Biopharma presents new data on STRO-002
PRAX Praxis Precision Medicines - 12/01/20
- Praxis CFO Stuart Chaffee transitions to part-time role as strategic advisor
- 11/17/20
- Praxis Precision expects to initiate Phase 2/3 trial for PRAX-114 in 1H21
- 11/09/20
- FDA places Praxis Precision Medicines' PRAX-114 IND on full clinical hold
- 10/30/20
- Envista rises 10.7%
- 08/04/20
- Dentsply Sirona, Patterson higher as Henry Schein discusses July trends on call
- 11/12/20
- Nkarta announces first patient treated in NKX101 trial
- 11/09/20
- Nkarta announces preclinical update on NKX019
- 10/05/20
- Nkarta CFO Matthew Plunkett steps down, Nadir Mahmood succeeds
- 07/24/20
- Ra Capital reports 17.2% stake in Nkarta
- 06/22/20
- Molecular Templates provides update on Phase 1 study of MT-5111
- 06/22/20
- Molecular Templates highlights ETB platform at AACR Annual Meeting
- 11/06/20
- Seres Therapeutics doses first patient in SER-301 trial
- 10/22/20
- Seres Therapeutics appoints David Ege as CTO, Jayne Gansler as CPO
- 09/11/20
- Seres Therapeutics announces FDA correspondence regarding SER-109 BLA
- 08/10/20
- Seres Therapeutics soars 170% after 'positive' results from Phase 3 ECOSPOR III
- 11/16/20
- Kodiak Sciences completes enrollment of DAZZLE study of KSI-301
- 10/05/20
- Kodiak Sciences: First patients treated in Phase 3 Studies of KSI-301
- 07/10/20
- Kodiak Sciences reports 'promising' safety data from KSI-301 Phase 1b study
- 11/13/20
- Insmed's Brensocatib receives EMA priority medicines designation for NCFBE
- 10/28/20
- Insmed: EC grants marketing authorization for ARIKAYCE
- 09/07/20
- Results from Insmed's Phase 2 WILLOW study of brensocatib published in NEJM
- 07/24/20
- Insmed's Arikayce for lung infections receives positive CHMP opinion in EU
- 11/30/20
- MacroGenics achieves $25M in milestones related to retifanlimab collaboration
- 11/19/20
- Eli Lilly, Incyte: FDA issues EUA for baricitinib/remdesivir combination
- 11/11/20
- Incyte, Xencor, MorphoSys to collaborate over tafasitamab-plamotamab combo
- 11/11/20
- Xoma earns $1M milestone payment from 2018 royalty purchase agreement
- 10/21/20
- Icon says COVID-19 impact reduced in recent months
- 07/22/20
- Icon shareholders vote in favor of all resolutions at annual meeting
- 07/28/20
- Hill-Rom announces commercial partnership with Aiva for hands-free communication
- 12/01/20
- Amicus initiates rolling BLA for AT-GAA in late-onset Pompe disease
- 11/05/20
- Amicus plans to initiate rolling BLA for AT-GAA in 2020
- 11/05/20
- Amicus sees FY20 Galafold revenue of $250M-$260M
- 10/12/20
- Amicus announces additional interim clinical data for AT-GTX-501
- 11/16/20
- Fate Therapeutics director sells 25K shares of common stock
- 08/19/20
- Fate Therapeutics appoints Edward Dulac as CFO
- 08/12/20
- Fate Therapeutics' FT516 receives support from CIRM Late Stage Preclinical grant
- 07/14/20
- Fate Therapeutics announces license agreement with Baylor College of Medicine
- 11/27/20
- Exelixis says Takeda receives approval for CABOMETYX in Japan
- 10/27/20
- Exelixis announces Takeda, Ono submit application for Cabometyx in Japan
- 10/26/20
- Exelixis announces 1st patient enrolled trial cohort evaluating XL092 in combo
- 10/19/20
- Bristol-Myers, Exelixis: FDA accepts sBLA, sNDA for OPDIVO/CABOMETYX combo
- 09/14/20
- Enanta initiates Phase 1 clinical study of EDP-297
- 08/28/20
- Enanta to present data from hepatitis B virus, NASH programs at EASL
- 07/09/20
- Enanta announces clinical trial progress for ED-514
- 11/16/20
- Dicerna gets $10M milestone from Lilly pact, Lilly initiates LY3561774 trial
- 11/16/20
- Dicerna presents data from phase1 trial of RG6346 for hep B at AASLD
- 10/22/20
- Dicerna reports 'positive' new interim data from PHYOX3 trial
- 09/16/20
- Dicerna appoints Ling Zeng as chief legal officer
- 11/30/20
- Cogent Biosciences appoints Brad Barnett as Chief Technology Officer
- 11/18/20
- Cogent Biosciences reports final Phase 2 results from PLX9486 in GIST
- 10/26/20
- Cogent Biosciences names Andrew Robbins as CEO, succeeding Chuck Wilson
- 11/12/20
- Compass Pathways expects cash, cash equivalents to fund operations into 2023
- 11/09/20
- Compass Pathways joins the Psychiatry Consortium
- 10/23/20
- Compass Pathways CEO says 'focus is on transforming mental healthcare'
- 10/05/20
- Citron touts mental health company Compass Pathways, sets $100 target on shares
- 11/24/20
- Bausch Health begins second of Phase 3 studies of NOV03
- 11/16/20
- Paulson & Co. buys Lear, cuts Tiffany in Q3
- 11/16/20
- Bausch Health reports in vitro data on Lumify, Besivance in SARS-CoV-2
- 10/29/20
- Bausch Health's rifaximin Receives FDA Orphan Designation
- 11/25/20
- Alexion granted orphan status for hematopoietic stem cell treatment
- 11/20/20
- Alexion receives marketing authorization from EC for Ultomiris 100mg
- 10/12/20
- Alexion gets FDA Aaproval for Ultomoris
- 10/06/20
- Alexion expects to raise FY20 revenue guidance by more than $200M
- 10/14/20 H.C. Wainwright
- Compass Pathways initiated with a Buy at H.C. Wainwright
- 10/13/20 Evercore ISI
- Compass Pathways initiated with an Outperform at Evercore ISI
- 10/13/20 Canaccord
- Compass Pathways initiated with a Buy at Canaccord
- 10/13/20 Berenberg
- Compass Pathways initiated with a Buy at Berenberg
- 11/23/20 Evercore ISI
- Insmed resumed with an Outperform at Evercore ISI
- 11/23/20 Evercore ISI
- Insmed resumed with an Outperform at Evercore ISI
- 10/12/20 Stifel
- Insmed resumed with a Buy at Stifel
- 04/23/20 JMP Securities
- JMP reiterates $50 target on Insmed on planned COVID-19 trial
- 11/20/20
- Fly Intel: Top five analyst initiations
- 11/20/20 Bernstein
- Alexion initiated with a Market Perform at Bernstein
- 11/19/20 Bernstein
- Alexion initiated with a Market Perform at Bernstein
- 11/05/20 Citi
- Alexion price target raised to $157 from $145 at Citi
- 11/24/20 RBC Capital
- Enanta price target lowered to $45 from $52 at RBC Capital
- 11/24/20 Evercore ISI
- Evercore cautious on Enanta into 2021, starts with Underperform
- 11/23/20 Evercore ISI
- Enanta initiated with an Underperform at Evercore ISI
- 10/26/20 Roth Capital
- Enanta price target raised to $107 from $104 at Roth Capital
- 10/06/20 Mizuho
- Nkarta CFO departure should not impact shares, says Mizuho
- 08/04/20 Mizuho
- Mizuho starts Nkarta with Buy rating, $34 price target
- 08/04/20 Evercore ISI
- Nkarta initiated with an Outperform at Evercore ISI
- 08/04/20 Stifel
- Nkarta initiated with a Buy at Stifel
- 11/04/20
- Fly Intel: Top five analyst downgrades
- 11/04/20
- Hill-Rom cut to Hold at Needham, expecting 'lost year' in FY21
- 11/04/20 Needham
- Hill-Rom downgraded to Hold from Buy at Needham
- 10/01/20 KeyBanc
- Hill-Rom price target lowered to $115 from $138 at KeyBanc
- 08/07/20 H.C. Wainwright
- Dicerna price target raised to $35 from $32 at H.C. Wainwright
- 07/01/20 Baird
- Dicerna elevated to Fresh Pick at Baird
- 05/12/20 RBC Capital
- Dicerna initiated with an Outperform at RBC Capital
- 05/11/20 Truist
- Dicerna price target raised to $33 from $28 at SunTrust
- $146.00 /
-3.175 (-2.13%) - 11/09/20 SVB Leerink
- Zimmer Biomet price target raised to $167 from $160 at SVB Leerink
- 11/09/20 Credit Suisse
- Zimmer Biomet price target raised to $106 from $99 at Credit Suisse
- 11/09/20 Baird
- Zimmer Biomet valuation discount to peers hard to justify, says at Baird
- 11/09/20 Oppenheimer
- Zimmer Biomet price target raised to $155 from $150 at Oppenheimer
- 11/06/20 RBC Capital
- Incyte price target lowered to $86 from $96 at RBC Capital
- 09/18/20 Piper Sandler
- Piper Sandler lays out next potential takeover targets in oncology
- 09/14/20 Mizuho
- Oncology 'fertile ground for M&A activity,' says Mizuho
- 08/05/20 Mizuho
- Incyte price target raised to $95 from $79 at Mizuho
- 09/08/20 Jefferies
- Molecular Templates initiated with a Buy at Jefferies
- 08/07/20
- Molecular Templates files $300M mixed securities shelf
- 05/12/20 Oppenheimer
- Molecular Templates price target raised to $22 from $16 at Oppenheimer
- 03/25/20
- Fly Intel: Top five analyst initiations
- 11/30/20
- Fly Intel: Top five analyst downgrades
- 11/30/20 JPMorgan
- Kodiak Sciences downgraded to Neutral on valuation at JPMorgan
- 11/30/20 JPMorgan
- Kodiak Sciences downgraded to Neutral from Overweight at JPMorgan
- 11/16/20 Morgan Stanley
- Morgan Stanley downgrades Kodiak to Equal Weight on lack of near-term catalysts
- 10/23/20 Deutsche Bank
- Icon price target raised to $179 from $170 at Deutsche Bank
- 10/23/20 Mizuho
- Icon price target raised to $217 from $195 at Mizuho
- 10/22/20 Credit Suisse
- Icon price target raised to $235 from $230 at Credit Suisse
- 07/27/20 Truist
- SunTrust raises price targets on select late-stage CROs
- 11/09/20 Oppenheimer
- Seres Therapeutics price target raised to $38 from $34 at Oppenheimer
- 11/09/20 Piper Sandler
- Seres Therapeutics price target raised to $49 from $40 at Piper Sandler
- 10/27/20 Oppenheimer
- Seres Therapeutics price target raised to $34 from $29 at Oppenheimer
- 10/26/20 Oppenheimer
- Seres Therapeutics price target raised to $34 from $29 at Oppenheimer
- 10/30/20 JPMorgan
- Envista price target raised to $30 from $28 at JPMorgan
- 10/30/20 Piper Sandler
- Envista price target raised to $28 from $22 at Piper Sandler
- 07/31/20 Piper Sandler
- Envista price target raised to $22 from $20 at Piper Sandler
- 06/16/20
- Fly Intel: Top five analyst initiations
- 10/26/20 Piper Sandler
- Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
- 09/22/20 Morgan Stanley
- Exelixis price target raised to $29 from $23 at Morgan Stanley
- 09/21/20 Piper Sandler
- Exelixis price target raised to $33 from $30 at Piper Sandler
- 06/30/20 Piper Sandler
- Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
- 11/24/20 Truist
- Fate Therapeutics price target raised to $65 from $40 at Truist
- 11/09/20 Citi
- Fate Therapeutics price target raised to $63 from $40 at Citi
- 11/08/20 Oppenheimer
- Fate Therapeutics price target raised to $60 from $40 at Oppenheimer
- 11/06/20 Piper Sandler
- Fate Therapeutics price target raised to $71 from $59 at Piper Sandler
- 11/11/20 Berenberg
- Biotechnology companies initiated at Berenberg
- 11/11/20 Berenberg
- Amicus initiated with a Hold at Berenberg
- 11/06/20 Baird
- Amicus price target raised to $25 from $20 at Baird
- 08/11/20 Citi
- Amicus price target raised to $20 from $15 at Citi
- 11/10/20 Wedbush
- Cogent Biosciences price target raised to $24 from $6 at Wedbush
- 10/14/20 Ladenburg
- Ladenburg starts Cogent Biosciences with Buy, $4 price target
- 10/14/20 Ladenburg
- Cogent Biosciences initiated with a Buy at Ladenburg
- 11/05/20 Piper Sandler
- Bausch Health price target lowered to $25 from $26 at Piper Sandler
- 10/26/20 Barclays
- Bausch Health price target raised to $29 from $28 at Barclays
- 09/17/20
- Fly Intel: Top five analyst upgrades
- 09/17/20 BofA
- Bausch Health upgraded to Neutral from Underperform at BofA
- 10/04/20 Goldman Sachs
- Translate Bio initiated with a Buy at Goldman Sachs
- 07/07/20 H.C. Wainwright
- Translate Bio price target raised to $32 from $18 at H.C. Wainwright
- 07/06/20
- Fly Intel: Top five analyst initiations
- 07/06/20 William Blair
- Translate Bio initiated with an Outperform at William Blair
- 11/06/20 Piper Sandler
- Sutro Biopharma price target raised to $22 from $20 at Piper Sandler
- 09/02/20 Jefferies
- Sutro Biopharma initiated with a Buy at Jefferies
- 07/16/20 Wells Fargo
- Sutro Biopharma initiated with an Overweight at Wells Fargo
PRAX Praxis Precision Medicines - 11/17/20 Piper Sandler
- Praxis Precision clinical hold looks like 'formality,' says Piper Sandler
- 11/11/20
- Fly Intel: Top five analyst initiations
- 11/11/20 Wedbush
- Wedbush bullish on Praxis Precision Medicines, initiates with an Outperform
- 11/11/20 Wedbush
- Praxis Precision Medicines initiated with an Outperform at Wedbush
- $146.00 /
-3.175 (-2.13%) - 11/06/20
- Zimmer Biomet not providing Q4 guidance
- 11/06/20
- Zimmer Biomet reports Q3 adjusted EPS $1.81, consensus $1.07
- 08/04/20
- Zimmer Biomet not providing FY20 guidance due to COVID-19
- 08/04/20
- Zimmer Biomet reports Q2 adj. EPS 5c, consensus (73c)
- 11/05/20
- Sutro Biopharma reports Q3 EPS 45c, consensus (51c)
- 08/06/20
- Sutro Biopharma reports Q2 EPS (94c), consensus (64c)
- 10/29/20
- Envista reports Q3 adjusted EPS 48c, consensus 9c
- 07/30/20
- Envista reports Q2 adjusted EPS (10c), consensus (22c)
- 11/05/20
- Molecular Templates cash, equivalents expected to fund operations into 2H22
- 11/05/20
- Molecular Templates reports Q3 EPS (47c), consensus (55c)
- 08/06/20
- Molecular Templates reports Q2 EPS (68c), consensus (36c)
- 11/09/20
- Seres Therapeutics reports Q3 EPS ,(36c) consensus (25c)
- 07/28/20
- Seres Therapeutics reports Q2 EPS (28c), consensus (26c)
- 11/09/20
- Kodiak Sciences reports Q3 EPS (80c), consensus (67c)
- 08/10/20
- Kodiak Sciences reports Q2 EPS (58c), consensus (66c)
- 10/29/20
- Insmed reports Q3 GAAP EPS (63c), consensus (61c)
- 08/06/20
- Insmed reports Q2 EPS (64c), consensus (63c)
- 11/05/20
- Incyte reports Q3 EPS 23c, consensus 75c
- 08/04/20
- Incyte reports Q2 EPS $1.24, consensus 87c
- 08/03/20
- Notable companies reporting before tomorrow's open
- 10/21/20
- Icon raises FY20 revenue view to $6.35-$6.50 from $6.00-$6.50
- 10/21/20
- Icon reports Q3 EPS $1.72, consensus $1.53
- 07/22/20
- Icon sees FY20 EPS $6.00-$6.50, consensus $5.95
- 07/22/20
- Icon reports Q2 adjusted EPS $1.20, consensus $1.10
- 11/06/20
- Hill-Rom sees FY21 adj. EPS $5.35-$5.45, consensus $5.38
- 11/06/20
- Hill-Rom sees Q1 adj. EPS $1.05-$1.10, consensus 96c
- 11/06/20
- Hill-Rom reports Q4 adj. EPS $1.17, consensus $1.07
- 07/31/20
- Hill-Rom reports Q3 adj. EPS $1.95, consensus $1.46
- 11/05/20
- Amicus reports Q3 EPS (25c), consensus (22c)
- 08/10/20
- Amicus sees 2020 Galafold revenue $250M-$260M, consensus $254.82M
- 08/10/20
- Amicus reports Q2 EPS (20c), consensus (26c)
- 07/17/20
- Amicus reaffirms 2020 Galafold revenue view $250M-$260M
- 11/05/20
- Fate Therapeutics reports Q3 EPS (40c), consensus (36c)
- 08/05/20
- Fate Therapeutics reports Q2 EPS (35c), consensus (27c)
- 11/05/20
- Exelixis sees FY20 revenue $900M-$950M, consensus $922M
- 11/05/20
- Exelixis reports Q3 adjusted EPS 4c, consensus 1c
- 08/06/20
- Exelixis sees FY20 revenue $900M-$950M, consensus $908.9M
- 08/06/20
- Exelixis reports Q2 EPS 25c, consensus 12c
- 11/23/20
- Enanta reports Q4 EPS ($1.46), consensus (95c)
- 08/04/20
- Enanta reports Q3 EPS (71c), consensus (84c)
- 11/05/20
- Dicerna reports Q3 EPS (29c), consensus (20c)
- 08/06/20
- Dicerna reports Q2 EPS (43c), consensus 10c
- 11/09/20
- Cogent Biosciences reports Q3 EPS ($5.07), consensus (14c)
- 11/12/20
- Compass Pathways reports Q3 EPS ($1.30), consensus (56c)
- 11/03/20
- Bausch Health reports Q3 adjusted EBITDA $948M, consensus $844.9M
- 11/03/20
- Bausch Health backs FY20 revenue view $7.8B-$8B, consensus $7.89B
- 11/02/20
- Notable companies reporting before tomorrow's open
- 10/29/20
- Alexion raises 2020 non-GAAP EPS view to $11.70-$12.00 from $10.65-$10.95
- 10/29/20
- Alexion reports Q3 non-GAAP EPS $3.24, consensus $2.60
- 10/28/20
- Notable companies reporting before tomorrow's open
|
Conference/Events
|
3rd Annual HealthCONx… 3rd Annual HealthCONx Virtual Conference will be held on December 1-3. ShowHide Related Items >><< - 08/04/20
- Zimmer Biomet saw incremental improvement in May, June
- 10/15/20
- Sanofi, Translate Bio: COVID-19 vaccine candidate induced high antibody levels
- 10/07/20
- Translate Bio announces upcoming presentations at NACFC
- 09/08/20
- Translate Bio resumes enrollment, dosing in Phase 1/2 trial of MRT5005
- 06/23/20
- Sanofi Pasteur, Translate Bio expand collaboration to develop mRNA vaccines
- 09/09/20
- Sutro Biopharma reports Phase 1 data of STRO-002 in ovarian cancer
- 09/02/20
- Sutro Biopharma reports 'promising' interim Phase 1 clinical data from STRO-002
- 08/25/20
- Sutro Biopharma achieves clinical supply milestone with Merck
- 06/22/20
- Sutro Biopharma presents new data on STRO-002
PRAX Praxis Precision Medicines - 12/01/20
- Praxis CFO Stuart Chaffee transitions to part-time role as strategic advisor
- 11/17/20
- Praxis Precision expects to initiate Phase 2/3 trial for PRAX-114 in 1H21
- 11/09/20
- FDA places Praxis Precision Medicines' PRAX-114 IND on full clinical hold
- 10/30/20
- Envista rises 10.7%
- 08/04/20
- Dentsply Sirona, Patterson higher as Henry Schein discusses July trends on call
- 11/12/20
- Nkarta announces first patient treated in NKX101 trial
- 11/09/20
- Nkarta announces preclinical update on NKX019
- 10/05/20
- Nkarta CFO Matthew Plunkett steps down, Nadir Mahmood succeeds
- 07/24/20
- Ra Capital reports 17.2% stake in Nkarta
- 06/22/20
- Molecular Templates provides update on Phase 1 study of MT-5111
- 06/22/20
- Molecular Templates highlights ETB platform at AACR Annual Meeting
- 11/06/20
- Seres Therapeutics doses first patient in SER-301 trial
- 10/22/20
- Seres Therapeutics appoints David Ege as CTO, Jayne Gansler as CPO
- 09/11/20
- Seres Therapeutics announces FDA correspondence regarding SER-109 BLA
- 08/10/20
- Seres Therapeutics soars 170% after 'positive' results from Phase 3 ECOSPOR III
- 11/16/20
- Kodiak Sciences completes enrollment of DAZZLE study of KSI-301
- 10/05/20
- Kodiak Sciences: First patients treated in Phase 3 Studies of KSI-301
- 07/10/20
- Kodiak Sciences reports 'promising' safety data from KSI-301 Phase 1b study
- 11/13/20
- Insmed's Brensocatib receives EMA priority medicines designation for NCFBE
- 10/28/20
- Insmed: EC grants marketing authorization for ARIKAYCE
- 09/07/20
- Results from Insmed's Phase 2 WILLOW study of brensocatib published in NEJM
- 07/24/20
- Insmed's Arikayce for lung infections receives positive CHMP opinion in EU
- 11/30/20
- MacroGenics achieves $25M in milestones related to retifanlimab collaboration
- 11/19/20
- Eli Lilly, Incyte: FDA issues EUA for baricitinib/remdesivir combination
- 11/11/20
- Incyte, Xencor, MorphoSys to collaborate over tafasitamab-plamotamab combo
- 11/11/20
- Xoma earns $1M milestone payment from 2018 royalty purchase agreement
- 10/21/20
- Icon says COVID-19 impact reduced in recent months
- 07/22/20
- Icon shareholders vote in favor of all resolutions at annual meeting
- 07/28/20
- Hill-Rom announces commercial partnership with Aiva for hands-free communication
- 12/01/20
- Amicus initiates rolling BLA for AT-GAA in late-onset Pompe disease
- 11/05/20
- Amicus plans to initiate rolling BLA for AT-GAA in 2020
- 11/05/20
- Amicus sees FY20 Galafold revenue of $250M-$260M
- 10/12/20
- Amicus announces additional interim clinical data for AT-GTX-501
- 11/16/20
- Fate Therapeutics director sells 25K shares of common stock
- 08/19/20
- Fate Therapeutics appoints Edward Dulac as CFO
- 08/12/20
- Fate Therapeutics' FT516 receives support from CIRM Late Stage Preclinical grant
- 07/14/20
- Fate Therapeutics announces license agreement with Baylor College of Medicine
- 11/27/20
- Exelixis says Takeda receives approval for CABOMETYX in Japan
- 10/27/20
- Exelixis announces Takeda, Ono submit application for Cabometyx in Japan
- 10/26/20
- Exelixis announces 1st patient enrolled trial cohort evaluating XL092 in combo
- 10/19/20
- Bristol-Myers, Exelixis: FDA accepts sBLA, sNDA for OPDIVO/CABOMETYX combo
- 09/14/20
- Enanta initiates Phase 1 clinical study of EDP-297
- 08/28/20
- Enanta to present data from hepatitis B virus, NASH programs at EASL
- 07/09/20
- Enanta announces clinical trial progress for ED-514
- 11/16/20
- Dicerna gets $10M milestone from Lilly pact, Lilly initiates LY3561774 trial
- 11/16/20
- Dicerna presents data from phase1 trial of RG6346 for hep B at AASLD
- 10/22/20
- Dicerna reports 'positive' new interim data from PHYOX3 trial
- 09/16/20
- Dicerna appoints Ling Zeng as chief legal officer
- 11/30/20
- Cogent Biosciences appoints Brad Barnett as Chief Technology Officer
- 11/18/20
- Cogent Biosciences reports final Phase 2 results from PLX9486 in GIST
- 10/26/20
- Cogent Biosciences names Andrew Robbins as CEO, succeeding Chuck Wilson
- 11/12/20
- Compass Pathways expects cash, cash equivalents to fund operations into 2023
- 11/09/20
- Compass Pathways joins the Psychiatry Consortium
- 10/23/20
- Compass Pathways CEO says 'focus is on transforming mental healthcare'
- 10/05/20
- Citron touts mental health company Compass Pathways, sets $100 target on shares
- 11/24/20
- Bausch Health begins second of Phase 3 studies of NOV03
- 11/16/20
- Paulson & Co. buys Lear, cuts Tiffany in Q3
- 11/16/20
- Bausch Health reports in vitro data on Lumify, Besivance in SARS-CoV-2
- 10/29/20
- Bausch Health's rifaximin Receives FDA Orphan Designation
- 11/25/20
- Alexion granted orphan status for hematopoietic stem cell treatment
- 11/20/20
- Alexion receives marketing authorization from EC for Ultomiris 100mg
- 10/12/20
- Alexion gets FDA Aaproval for Ultomoris
- 10/06/20
- Alexion expects to raise FY20 revenue guidance by more than $200M
- 10/14/20 H.C. Wainwright
- Compass Pathways initiated with a Buy at H.C. Wainwright
- 10/13/20 Evercore ISI
- Compass Pathways initiated with an Outperform at Evercore ISI
- 10/13/20 Canaccord
- Compass Pathways initiated with a Buy at Canaccord
- 10/13/20 Berenberg
- Compass Pathways initiated with a Buy at Berenberg
- 11/23/20 Evercore ISI
- Insmed resumed with an Outperform at Evercore ISI
- 11/23/20 Evercore ISI
- Insmed resumed with an Outperform at Evercore ISI
- 10/12/20 Stifel
- Insmed resumed with a Buy at Stifel
- 04/23/20 JMP Securities
- JMP reiterates $50 target on Insmed on planned COVID-19 trial
- 11/20/20
- Fly Intel: Top five analyst initiations
- 11/20/20 Bernstein
- Alexion initiated with a Market Perform at Bernstein
- 11/19/20 Bernstein
- Alexion initiated with a Market Perform at Bernstein
- 11/05/20 Citi
- Alexion price target raised to $157 from $145 at Citi
- 11/24/20 RBC Capital
- Enanta price target lowered to $45 from $52 at RBC Capital
- 11/24/20 Evercore ISI
- Evercore cautious on Enanta into 2021, starts with Underperform
- 11/23/20 Evercore ISI
- Enanta initiated with an Underperform at Evercore ISI
- 10/26/20 Roth Capital
- Enanta price target raised to $107 from $104 at Roth Capital
- 10/06/20 Mizuho
- Nkarta CFO departure should not impact shares, says Mizuho
- 08/04/20 Mizuho
- Mizuho starts Nkarta with Buy rating, $34 price target
- 08/04/20 Evercore ISI
- Nkarta initiated with an Outperform at Evercore ISI
- 08/04/20 Stifel
- Nkarta initiated with a Buy at Stifel
- 11/04/20
- Fly Intel: Top five analyst downgrades
- 11/04/20
- Hill-Rom cut to Hold at Needham, expecting 'lost year' in FY21
- 11/04/20 Needham
- Hill-Rom downgraded to Hold from Buy at Needham
- 10/01/20 KeyBanc
- Hill-Rom price target lowered to $115 from $138 at KeyBanc
- 08/07/20 H.C. Wainwright
- Dicerna price target raised to $35 from $32 at H.C. Wainwright
- 07/01/20 Baird
- Dicerna elevated to Fresh Pick at Baird
- 05/12/20 RBC Capital
- Dicerna initiated with an Outperform at RBC Capital
- 05/11/20 Truist
- Dicerna price target raised to $33 from $28 at SunTrust
- 11/09/20 SVB Leerink
- Zimmer Biomet price target raised to $167 from $160 at SVB Leerink
- 11/09/20 Credit Suisse
- Zimmer Biomet price target raised to $106 from $99 at Credit Suisse
- 11/09/20 Baird
- Zimmer Biomet valuation discount to peers hard to justify, says at Baird
- 11/09/20 Oppenheimer
- Zimmer Biomet price target raised to $155 from $150 at Oppenheimer
- 11/06/20 RBC Capital
- Incyte price target lowered to $86 from $96 at RBC Capital
- 09/18/20 Piper Sandler
- Piper Sandler lays out next potential takeover targets in oncology
- 09/14/20 Mizuho
- Oncology 'fertile ground for M&A activity,' says Mizuho
- 08/05/20 Mizuho
- Incyte price target raised to $95 from $79 at Mizuho
- 09/08/20 Jefferies
- Molecular Templates initiated with a Buy at Jefferies
- 08/07/20
- Molecular Templates files $300M mixed securities shelf
- 05/12/20 Oppenheimer
- Molecular Templates price target raised to $22 from $16 at Oppenheimer
- 03/25/20
- Fly Intel: Top five analyst initiations
- 11/30/20
- Fly Intel: Top five analyst downgrades
- 11/30/20 JPMorgan
- Kodiak Sciences downgraded to Neutral on valuation at JPMorgan
- 11/30/20 JPMorgan
- Kodiak Sciences downgraded to Neutral from Overweight at JPMorgan
- 11/16/20 Morgan Stanley
- Morgan Stanley downgrades Kodiak to Equal Weight on lack of near-term catalysts
- 10/23/20 Deutsche Bank
- Icon price target raised to $179 from $170 at Deutsche Bank
- 10/23/20 Mizuho
- Icon price target raised to $217 from $195 at Mizuho
- 10/22/20 Credit Suisse
- Icon price target raised to $235 from $230 at Credit Suisse
- 07/27/20 Truist
- SunTrust raises price targets on select late-stage CROs
- 11/09/20 Oppenheimer
- Seres Therapeutics price target raised to $38 from $34 at Oppenheimer
- 11/09/20 Piper Sandler
- Seres Therapeutics price target raised to $49 from $40 at Piper Sandler
- 10/27/20 Oppenheimer
- Seres Therapeutics price target raised to $34 from $29 at Oppenheimer
- 10/26/20 Oppenheimer
- Seres Therapeutics price target raised to $34 from $29 at Oppenheimer
- 10/30/20 JPMorgan
- Envista price target raised to $30 from $28 at JPMorgan
- 10/30/20 Piper Sandler
- Envista price target raised to $28 from $22 at Piper Sandler
- 07/31/20 Piper Sandler
- Envista price target raised to $22 from $20 at Piper Sandler
- 06/16/20
- Fly Intel: Top five analyst initiations
- 10/26/20 Piper Sandler
- Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
- 09/22/20 Morgan Stanley
- Exelixis price target raised to $29 from $23 at Morgan Stanley
- 09/21/20 Piper Sandler
- Exelixis price target raised to $33 from $30 at Piper Sandler
- 06/30/20 Piper Sandler
- Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
- 11/24/20 Truist
- Fate Therapeutics price target raised to $65 from $40 at Truist
- 11/09/20 Citi
- Fate Therapeutics price target raised to $63 from $40 at Citi
- 11/08/20 Oppenheimer
- Fate Therapeutics price target raised to $60 from $40 at Oppenheimer
- 11/06/20 Piper Sandler
- Fate Therapeutics price target raised to $71 from $59 at Piper Sandler
- 11/11/20 Berenberg
- Biotechnology companies initiated at Berenberg
- 11/11/20 Berenberg
- Amicus initiated with a Hold at Berenberg
- 11/06/20 Baird
- Amicus price target raised to $25 from $20 at Baird
- 08/11/20 Citi
- Amicus price target raised to $20 from $15 at Citi
- 11/10/20 Wedbush
- Cogent Biosciences price target raised to $24 from $6 at Wedbush
- 10/14/20 Ladenburg
- Ladenburg starts Cogent Biosciences with Buy, $4 price target
- 10/14/20 Ladenburg
- Cogent Biosciences initiated with a Buy at Ladenburg
- 11/05/20 Piper Sandler
- Bausch Health price target lowered to $25 from $26 at Piper Sandler
- 10/26/20 Barclays
- Bausch Health price target raised to $29 from $28 at Barclays
- 09/17/20
- Fly Intel: Top five analyst upgrades
- 09/17/20 BofA
- Bausch Health upgraded to Neutral from Underperform at BofA
- 10/04/20 Goldman Sachs
- Translate Bio initiated with a Buy at Goldman Sachs
- 07/07/20 H.C. Wainwright
- Translate Bio price target raised to $32 from $18 at H.C. Wainwright
- 07/06/20
- Fly Intel: Top five analyst initiations
- 07/06/20 William Blair
- Translate Bio initiated with an Outperform at William Blair
- 11/06/20 Piper Sandler
- Sutro Biopharma price target raised to $22 from $20 at Piper Sandler
- 09/02/20 Jefferies
- Sutro Biopharma initiated with a Buy at Jefferies
- 07/16/20 Wells Fargo
- Sutro Biopharma initiated with an Overweight at Wells Fargo
PRAX Praxis Precision Medicines - 11/17/20 Piper Sandler
- Praxis Precision clinical hold looks like 'formality,' says Piper Sandler
- 11/11/20
- Fly Intel: Top five analyst initiations
- 11/11/20 Wedbush
- Wedbush bullish on Praxis Precision Medicines, initiates with an Outperform
- 11/11/20 Wedbush
- Praxis Precision Medicines initiated with an Outperform at Wedbush
- 11/06/20
- Zimmer Biomet not providing Q4 guidance
- 11/06/20
- Zimmer Biomet reports Q3 adjusted EPS $1.81, consensus $1.07
- 08/04/20
- Zimmer Biomet not providing FY20 guidance due to COVID-19
- 08/04/20
- Zimmer Biomet reports Q2 adj. EPS 5c, consensus (73c)
- 11/05/20
- Sutro Biopharma reports Q3 EPS 45c, consensus (51c)
- 08/06/20
- Sutro Biopharma reports Q2 EPS (94c), consensus (64c)
- 10/29/20
- Envista reports Q3 adjusted EPS 48c, consensus 9c
- 07/30/20
- Envista reports Q2 adjusted EPS (10c), consensus (22c)
- 11/05/20
- Molecular Templates cash, equivalents expected to fund operations into 2H22
- 11/05/20
- Molecular Templates reports Q3 EPS (47c), consensus (55c)
- 08/06/20
- Molecular Templates reports Q2 EPS (68c), consensus (36c)
- 11/09/20
- Seres Therapeutics reports Q3 EPS ,(36c) consensus (25c)
- 07/28/20
- Seres Therapeutics reports Q2 EPS (28c), consensus (26c)
- 11/09/20
- Kodiak Sciences reports Q3 EPS (80c), consensus (67c)
- 08/10/20
- Kodiak Sciences reports Q2 EPS (58c), consensus (66c)
- 10/29/20
- Insmed reports Q3 GAAP EPS (63c), consensus (61c)
- 08/06/20
- Insmed reports Q2 EPS (64c), consensus (63c)
- 11/05/20
- Incyte reports Q3 EPS 23c, consensus 75c
- 08/04/20
- Incyte reports Q2 EPS $1.24, consensus 87c
- 08/03/20
- Notable companies reporting before tomorrow's open
- 10/21/20
- Icon raises FY20 revenue view to $6.35-$6.50 from $6.00-$6.50
- 10/21/20
- Icon reports Q3 EPS $1.72, consensus $1.53
- 07/22/20
- Icon sees FY20 EPS $6.00-$6.50, consensus $5.95
- 07/22/20
- Icon reports Q2 adjusted EPS $1.20, consensus $1.10
- 11/06/20
- Hill-Rom sees FY21 adj. EPS $5.35-$5.45, consensus $5.38
- 11/06/20
- Hill-Rom sees Q1 adj. EPS $1.05-$1.10, consensus 96c
- 11/06/20
- Hill-Rom reports Q4 adj. EPS $1.17, consensus $1.07
- 07/31/20
- Hill-Rom reports Q3 adj. EPS $1.95, consensus $1.46
- 11/05/20
- Amicus reports Q3 EPS (25c), consensus (22c)
- 08/10/20
- Amicus sees 2020 Galafold revenue $250M-$260M, consensus $254.82M
- 08/10/20
- Amicus reports Q2 EPS (20c), consensus (26c)
- 07/17/20
- Amicus reaffirms 2020 Galafold revenue view $250M-$260M
- 11/05/20
- Fate Therapeutics reports Q3 EPS (40c), consensus (36c)
- 08/05/20
- Fate Therapeutics reports Q2 EPS (35c), consensus (27c)
- 11/05/20
- Exelixis sees FY20 revenue $900M-$950M, consensus $922M
- 11/05/20
- Exelixis reports Q3 adjusted EPS 4c, consensus 1c
- 08/06/20
- Exelixis sees FY20 revenue $900M-$950M, consensus $908.9M
- 08/06/20
- Exelixis reports Q2 EPS 25c, consensus 12c
- 11/23/20
- Enanta reports Q4 EPS ($1.46), consensus (95c)
- 08/04/20
- Enanta reports Q3 EPS (71c), consensus (84c)
- 11/05/20
- Dicerna reports Q3 EPS (29c), consensus (20c)
- 08/06/20
- Dicerna reports Q2 EPS (43c), consensus 10c
- 11/09/20
- Cogent Biosciences reports Q3 EPS ($5.07), consensus (14c)
- 11/12/20
- Compass Pathways reports Q3 EPS ($1.30), consensus (56c)
- 11/03/20
- Bausch Health reports Q3 adjusted EBITDA $948M, consensus $844.9M
- 11/03/20
- Bausch Health backs FY20 revenue view $7.8B-$8B, consensus $7.89B
- 11/02/20
- Notable companies reporting before tomorrow's open
- 10/29/20
- Alexion raises 2020 non-GAAP EPS view to $11.70-$12.00 from $10.65-$10.95
- 10/29/20
- Alexion reports Q3 non-GAAP EPS $3.24, consensus $2.60
- 10/28/20
- Notable companies reporting before tomorrow's open
|